UBS Group »

Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by UBS Group

Quarter-by-quarter ownership of Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Halozyme Therapeutics Inc Note 1.000 8/1

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics Inc Note 1.000 8/1 held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics Inc Note 1.000 8/1 by UBS Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $1.9k 2.0k 0.93

More positions owned by UBS Group

Microsoft Corporation (MSFT)
Apple Call Option (AAPL)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
NVIDIA Corporation (NVDA)
Ubs Group SHS (UBS)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr 20 Yr Tr Bd Etf (TLT)
Union Pacific Corporation (UNP)
Alphabet Cap Stk Cl C Put Option (GOOG)
Meta Platforms Cl A (META)

View all positions for UBS Group

Top funds holding Halozyme Therapeutics Inc Note 1.000 8/1

M&g Investment Management
Calamos Advisors
Wolverine Asset Management
MacKay Shields
Citadel Advisors
Polar Securities
Millennium Management
Bank Of Montreal
Kohlberg Kravis Roberts & Co
D. E. Shaw & Co
Absolute Investment Advisers
Leucadia National Corporation
SSI Investment Management
CSS
Readystate Asset Management

View all funds holding Halozyme Therapeutics Inc Note 1.000 8/1